09/17/2026
Psychedelic medicine continues to move into the mainstream.
A new Washington Post story follows a woman who lived for years with persistent headaches, fatigue and brain fog following treatment for Lyme disease β and her experience participating in a Johns Hopkins study involving supervised psilocybin sessions.
The small pilot study followed 20 participants with persistent symptoms after Lyme disease treatment. Six months after receiving psilocybin, participants reported an average reduction of approximately 40% in their overall symptoms, along with improvements in energy, sleep and mood.
The study was small and did not include a control group, so researchers cannot say that psilocybin caused these improvements. But the findings add to a growing body of research examining how psychedelic experiences may affect the brain, neuroplasticity, mental health and our relationship with chronic illness.
Perhaps one of the most interesting parts of the story wasn't simply symptom relief.
It was a change in perspective.
The woman featured in the article described the experience as fundamentally changing how she copes with illness and how she sees herself in the world.
That distinction between simply treating symptoms and exploring deeper healing is one of the reasons this field deserves thoughtful, responsible research.
Weβre encouraged to see conversations around psilocybin becoming increasingly grounded in science, safety, preparation and professional support.
β Bend Inner Alchemy
Elizabeth Richwine is at the frontier of a psychedelic boom that could transform medicine β and create a massive new industry.